U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C8H13NO3S2
Molecular Weight 235.324
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LIMAZOCIC

SMILES

CC1(C)CSSC[C@H](NC1=O)C(O)=O

InChI

InChIKey=PTARWFJHCZHOGS-YFKPBYRVSA-N
InChI=1S/C8H13NO3S2/c1-8(2)4-14-13-3-5(6(10)11)9-7(8)12/h5H,3-4H2,1-2H3,(H,9,12)(H,10,11)/t5-/m0/s1

HIDE SMILES / InChI

Molecular Formula C8H13NO3S2
Molecular Weight 235.324
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Limazocic is a cyclic disulfide compound newly synthesized as a hepatoprotective agent. It has a protective effect against both chronic liver injuries induced by carbon tetrachloride (CCL) and swine serum and several chemically induced acute liver injuries. The inhibitory effects of limazocic on immunologically induced liver injuries in mice have also been demonstrated and furthermore, limazocic has been shown to have immunomodulatory effects such as induction of cytotoxic cell activities and modulation of interleukin-2 and interferon-gamma production. Limazocic had a markedly inhibitory effect on ANIT-induced intrahepatic cholestasis in rats. Limazocic suppresses VEGF production and reduces vascular leakage and the growth of mouse experimental choroidal neovascularization.

Approval Year

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
100 or 300 mg/kg, three times at 4h intervals
Route of Administration: Oral
Substance Class Chemical
Record UNII
FY2I4AJB16
Record Status Validated (UNII)
Record Version